ArticleFluids and barriers of the CNS2026
Novel paracellular marker based on ᴅ-dipeptide structure for highly sensitive quantification with UPLC-MS/MS for in vitro and in vivo blood-brain barrier permeability analysis.
Article in Fluids and barriers of the CNS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe blood-brain barrier (BBB) paracellular permeability must be evaluated in various contexts in vitro and in vivo, including pharmacological evaluation of drug candidates, investigations of pathological changes in disease and model development. However, most available paracellular marker substances are either radioactive, lack sensitivity and thereby require large sample volumes, or they can influence the BBB themselves via osmotic pressure. Moreover, in drug permeability studies, an adequate paracellular marker should be detectable in the same sample as the compound being tested, ideally applying the same analytical technology.
methodsWe rationally designed a novel permeability marker to be highly sensitively measurable with ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS); to be not a potential substrate of solute carriers or transporters; stable against enzymatic digestion and well tolerated. We evaluated this novel permeability marker in vitro in Transwell® models with four different cell types (MDCK II, hCMEC/D3, primary and from induced pluripotent stem cells derived brain capillary endothelial cells) and cross-validated these results with known fluorescence markers. We further analyzed its in vivo pharmacokinetics and brain-to-plasma ratio in healthy Swiss mice. Possible interactions with LAT-1 and PepT1 were evaluated with uptake and/or inhibition assays.
resultsBased on non-canonical and ᴅ-dipeptide structure, the developed marker ᴅ-methyl-tyrosinyl-ᴅ-ornithine (ᴅ-Tyr(Me)Orn) is hydrophilic and with low molecular weight (309 Da), it enables a low endogenous background and is readily available through peptide synthesis, also as isotopically labeled derivative. The developed UPLC-MS/MS quantification assay allows a highly sensitive measurement in different matrices (lower limit of quantification: 0.05 ng/mL cell medium, lysed cells, 0.1 ng/mL mouse plasma; 3 ng/g, mouse brain). In the well-known MDCK II Transwell® model, it revealed a suitable Papp of 5.13 ± 1.08 × 10− 7 cm/s. Using the marker ᴅ-Tyr(Me)Orn it was further possible to compare the tightness of three brain capillary endothelial cell models. The time dependent distribution and in vivo pharmacokinetics was determined in healthy Swiss mice and revealed a constantly low brain concentration and brain-to-plasma ratio.
conclusionWe developed a highly feasible new paracellular marker, easily adaptable in various experimental designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.